Should I buy or sell Chugai Pharmaceutical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHGCY shares. View CHGCY analyst ratings or view top-rated stocks .

How have CHGCY shares performed in 2024?

Chugai Pharmaceutical's stock was trading at $18.85 at the start of the year. Since then, CHGCY shares have decreased by 10.9% and is now trading at $16.79. View the best growth stocks for 2024 here .

Are investors shorting Chugai Pharmaceutical?

Chugai Pharmaceutical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 111,100 shares, an increase of 439.3% from the March 15th total of 20,600 shares. Based on an average daily volume of 216,900 shares, the days-to-cover ratio is presently 0.5 days. View Chugai Pharmaceutical's Short Interest .

How were Chugai Pharmaceutical's earnings last quarter?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) released its earnings results on Thursday, February, 1st. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $1.85 billion for the quarter. Chugai Pharmaceutical had a net margin of 29.14% and a trailing twelve-month return on equity of 21.02%.

Is Chugai Pharmaceutical a good dividend stock?

Chugai Pharmaceutical (OTCMKTS:CHGCY) pays an annual dividend of $0.18 per share and currently has a dividend yield of 1.07%. The dividend payout ratio is 25.71%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHGCY will have a dividend payout ratio of 24.32% next year. This indicates that the company will be able to sustain or increase its dividend.

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Free CHGCY Stock Alerts

$16.79

+0.15 (+0.90%)

(As of 04/23/2024 ET)

Compare

Today's Range: $16.47
▼
$17.21
50-Day Range: $15.89
▼
$21.94
52-Week Range: $12.28
▼
$22.61

Volume: 176,502 shs
Average Volume: 354,679 shs
Market Capitalization: $55.24 billion

P/E Ratio: 23.99
Dividend Yield: 1.07%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades SEC Filings Short Interest

Get Chugai Pharmaceutical alerts:

Chugai Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 5.71%
From $0.70 to $0.74 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.66 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Chugai Pharmaceutical.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of Chugai Pharmaceutical have been sold short.
Short Interest Ratio / Days to Cover
Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Chugai Pharmaceutical has recently increased by 439.32%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Chugai Pharmaceutical pays a meaningful dividend of 1.07%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Chugai Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Chugai Pharmaceutical is 25.71%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 24.32% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CHGCY.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Chugai Pharmaceutical this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Chugai Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.01% of the stock of Chugai Pharmaceutical is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Chugai Pharmaceutical are expected to grow by 5.71% in the coming year, from $0.70 to $0.74 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chugai Pharmaceutical is 23.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.29.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chugai Pharmaceutical is 23.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 177.99.
Price to Book Value per Share Ratio
Chugai Pharmaceutical has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY)

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

CHGCY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CHGCY Stock News Headlines

April 23, 2024 | markets.businessinsider.com

Chugai Pharmaceutical is about to announce its earnings — here's what Wall Street expects

February 25, 2024 | msn.com

Chugai Pharmaceutical Co., - Depositary Receipt () (CHGCY) Price Target Increased by 5.85% to 19.64

April 24, 2024 | Stansberry Research (Ad)

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

February 21, 2024 | au.finance.yahoo.com

Chugai Pharmaceutical Co Ltd (CUP.HA)

February 18, 2024 | seekingalpha.com

Week In Review: LianBio To Close Operations; Will Pay $528M To Shareholders

February 17, 2024 | finance.yahoo.com

Chugai Pharmaceutical Co., Ltd. (CHGCY)

February 16, 2024 | wsj.com

Chugai Pharmaceutical Co. Ltd. ADR

February 13, 2024 | au.finance.yahoo.com

Chugai Pharmaceutical Co Ltd (CUP.MU)

April 24, 2024 | Stansberry Research (Ad)

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

February 6, 2024 | investing.com

Chugai Pharmaceutical Co., Ltd. (4519)

January 25, 2024 | finance.yahoo.com

U.S. Stocks Rise as Economic Growth Continues

January 25, 2024 | finance.yahoo.com

U.S. Stocks Rise After Strong GDP Data

January 25, 2024 | finance.yahoo.com

Futures Steady With More Earnings in Focus

January 24, 2024 | finance.yahoo.com

Nikkei Down 0.3%, Dragged by Tech, Pharmaceutical Stocks

January 4, 2024 | morningstar.com

Chugai Pharmaceutical Co Ltd ADR CHGCY

December 17, 2023 | seekingalpha.com

Week In Review: SystImmune Out-Licenses Global Rights For ADC To BMS In $8.4B Deal

December 16, 2023 | msn.com

Chugai Pharmaceutical Co Ltd - ADR (CHGCY) Price Target Increased by 14.02% to 19.28

December 12, 2023 | finance.yahoo.com

Chugai Pharmaceutical Co., Ltd. (CUP0.MU)

November 29, 2023 | morningstar.com

Chugai Pharmaceutical Co Ltd CUP

November 18, 2023 | morningstar.com

Chugai Pharmaceutical Co Ltd

October 23, 2023 | markets.businessinsider.com

Chugai Pharmaceutical earnings: here's what to expect

October 12, 2023 | finance.yahoo.com

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why

October 5, 2023 | finance.yahoo.com

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know

September 1, 2023 | investing.com

TOPIX Pharmaceutical (IPHAM.T)

August 19, 2023 | wsj.com

Chugai Pharmaceutical Co. Ltd.

August 3, 2023 | msn.com

Chugai Pharmaceutical (CHGCF) Price Target Decreased by 6.55% to 30.71

April 26, 2023 | markets.businessinsider.com

Here's what to expect from Chugai Pharmaceutical's earnings report

See More Headlines

Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/01/2024
Today: 4/23/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drugs, proprietaries, & sundries
Sub-Industry: N/A
Current Symbol: OTCMKTS:CHGCY
CUSIP: N/A
CIK: 1453934
Web: www.chugai-pharm.co.jp
Phone: (133) 281-6611
Fax: N/A
Employees: 7,771
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.70
Trailing P/E Ratio: 23.99
Forward P/E Ratio: 23.99
P/E Growth: N/A
Net Income: $2.31 billion
Net Margins: 29.14%
Pretax Margin: 39.94%
Return on Equity: 21.02%
Return on Assets: 17.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.74
Quick Ratio: 3.79

Sales & Book Value

Annual Sales: $7.93 billion
Price / Sales: 6.97
Cash Flow: $0.93 per share
Price / Cash Flow: 17.96
Book Value: $3.51 per share
Price / Book: 4.78

Miscellaneous

Outstanding Shares: 3,289,980,000
Free Float: N/A
Market Cap: $55.24 billion
Optionable: Not Optionable
Beta: 0.78

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Osamu Okuda (Age 61)
President, CEO & Representative Director
Comp: $1.44M
Mr. Toshiaki Itagaki (Age 64)
Head of Finance Supervisory Division, CFO & Executive VP
Toshiya Sasai
Executive of Investor Relations Group & Corporate Communications Department
Mr. Shinji Hidaka
Executive VP and Head of Marketing & Sales Division
Mr. Junichi Ebihara
Executive Vice President
Dr. Yoshiaki Ohashi (Age 64)
SVP & Full-time Audit Supervisory Board Member
Mr. Tetsuya Yamaguchi
Executive VP and Head of Project, Lifecycle Management & Foundation Medicine Unit
Mr. Yoshiyuki Yano
Executive Vice President
Ms. Satoko Shisai (Age 61)
Executive VP & Head of Digital Transformation Unit
Dr. Shigehiro Yamada Ph.D. (Age 60)
Head of Sustainability Department and Full-Time Audit & Supervisory Board Member

Key Competitors

View All Competitors

Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

Chugai Pharmaceutical has a strong product portfolio with a focus on oncology, including innovative drugs like Avastin, Tecentriq, and Perjeta, which have shown promising results in the market.
The company has a solid financial performance, as evidenced by its recent quarterly earnings report where it beat analysts' consensus estimates, showcasing its profitability and growth potential.
Chugai Pharmaceutical's strategic alliances and collaboration with Roche Group provide a strong backing for research, development, and market expansion, enhancing its competitive position in the industry.
With a market cap of $72.28 billion, Chugai Pharmaceutical is a well-established player in the pharmaceutical sector, offering stability and long-term investment opportunities for investors.
Chugai Pharmaceutical's stock price has been showing positive momentum, trading at $21.97 with a 52-week high of $22.61, indicating potential for capital appreciation.

Cons

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

Chugai Pharmaceutical's stock experienced a significant increase in short interest in February, which may indicate increased market volatility and potential downside risk for investors.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

CHGCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Chugai Pharmaceutical stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHGCY shares.
View CHGCY analyst ratings or view top-rated stocks.
How have CHGCY shares performed in 2024?: Chugai Pharmaceutical's stock was trading at $18.85 at the start of the year. Since then, CHGCY shares have decreased by 10.9% and is now trading at $16.79.
View the best growth stocks for 2024 here.
Are investors shorting Chugai Pharmaceutical?: Chugai Pharmaceutical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 111,100 shares, an increase of 439.3% from the March 15th total of 20,600 shares. Based on an average daily volume of 216,900 shares, the days-to-cover ratio is presently 0.5 days.
View Chugai Pharmaceutical's Short Interest.
How were Chugai Pharmaceutical's earnings last quarter?: Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) released its earnings results on Thursday, February, 1st. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $1.85 billion for the quarter. Chugai Pharmaceutical had a net margin of 29.14% and a trailing twelve-month return on equity of 21.02%.

Is Chugai Pharmaceutical a good dividend stock?: Chugai Pharmaceutical (OTCMKTS:CHGCY) pays an annual dividend of $0.18 per share and currently has a dividend yield of 1.07%. The dividend payout ratio is 25.71%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHGCY will have a dividend payout ratio of 24.32% next year. This indicates that the company will be able to sustain or increase its dividend.
How do I buy shares of Chugai Pharmaceutical?: Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CHGCY) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Chugai Pharmaceutical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY)

CHGCY Stock Price History

CHGCY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

Pros

Cons

CHGCY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™